Actively Recruiting

Age: 6Months +
All Genders
Healthy Volunteers
ID06237790

A Comparative Analysis of Speech Perception Between Cochlear Implant Patients and DFNB9 Patients Receiving Gene Therapy

Led by Eye & ENT Hospital of Fudan University · Updated on 2025-09-04

180

Participants Needed

6

Research Sites

63 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are exploring and comparing how patients perceive sounds after receiving either cochlear implants or gene therapy for congenital deafness. This study aims to understand differences in speech perception in various environments, music appreciation, and directional hearing between these two treatments. By assessing cognitive and psychological factors alongside auditory development, the study hopes to inform better rehabilitation plans for gene therapy patients. The study includes two groups of congenital deafness patients: those who have cochlear implants and those who have undergone gene therapy for autosomal recessive deafness 9 (DFNB9). Patients receive standard postoperative care and follow-up. The evaluation covers multiple aspects such as speech perception in quiet and noisy settings, cognitive function, psychological status, and auditory cortex growth over time. Participants will be assessed before treatment and at weeks 13, 26, and 52 after intervention. Evaluations include tests of auditory speech perception, cognitive abilities, psychological health, and brain development related to hearing. The study requires participants and their guardians to provide informed consent and cooperate with follow-up visits. Healthy individuals with normal hearing are also included as controls. The goal is to compare outcomes between the two treatments over one year.

CONDITIONS

Brief Title

A Comparative Analysis of Speech Perception Between Cochlear Implant Patients and DFNB9 Patients Receiving Gene Therapy

Who Can Participate

Age: 6Months +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with congenital hearing loss with hearing thresholds 65 dB who have received or plan to receive gene therapy or cochlear implant surgery
  • Healthy participants with normal bilateral hearing thresholds (40 dB), matched by age and sex
  • Age 6 months or older, any gender
  • Mandarin Chinese as the native language
  • Participants and guardians must provide informed consent and commit to follow-up visits
  • Able to communicate effectively with guardian assistance and willing to cooperate with researchers
  • Guardians should understand the trial and have appropriate expectations
Not Eligible

You will not qualify if you...

  • Other ear disorders affecting surgery or study results, such as ear malformations or nerve abnormalities
  • Severe congenital diseases
  • Severe or acute systemic diseases like active infections or organ failure
  • Low immunity, immune deficiency, or history of organ transplant
  • History of neurological or mental disorders like epilepsy or dementia
  • Contraindications for surgery or anesthesia, including recent cardiovascular events or medication allergies
  • For gene therapy group: hearing not restored by gene therapy
  • For cochlear implant group: hereditary syndromic deafness or other conditions affecting evaluation
  • Any other conditions deemed unsuitable by investigators

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 1 year

Participants receive either gene therapy or cochlear implant surgery as part of their treatment for congenital hearing loss.

Visits at preoperation, Week 13, Week 26, and Week 52

Follow-up

Duration - Up to 1 year

Participants undergo evaluations of auditory speech perception, cognitive function, psychological status, and auditory cortex development after treatment.

Visits at Week 13, Week 26, and Week 52

Trial Site Locations

Total: 6 locations

1

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China, 100730

Not Yet Recruiting

2

The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China, 450052

Not Yet Recruiting

3

The Second Xiangya Hospital of Central South University

Changsha, Hunan, China, 410011

Not Yet Recruiting

4

The First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China, 330006

Not Yet Recruiting

5

Eye & ENT Hospital of Fudan University

Shanghai, Shanghai Municipality, China, 200031

Actively Recruiting

6

West China Hospital, Sichuan University

Chengdu, Sichuan, China, 610041

Not Yet Recruiting

Loading map...

Research Team

Y

Yilai Shu, M.D. & Ph.D.

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

A Double-Blinded, Placebo-Controlled, Randomized Phase 1/2a ...

Central Auditory Processing Disorder

Actively Recruiting

1 location

Accurate Assessment and Intervention Research on Newborn Who...

Genetic Disease

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here